We formulate and encapsulate drugs for efficient delivery and optimal effect, offer advanced characterization of active substances and investigate their effect on the body.
We apply nanomedicine in:
| Nanoformulation technologies | Material science | Physico-chemical characterization | In vitro assays | In vivo studies |
Many drugs are either unstable or difficult to administrate and deliver. We provide tailored nanoformulation solutions for a wide range of small molecular drugs and biomolecules.
We use emulsion-based, nanoprecipitation, self-assembly and layer-by-layer methods to produce:
SINTEF provides expertise within material chemistry, ranging from surface modification to chemical synthesis.
SINTEF has state-of-the art infrastructure for performing standardized and custom characterization of nanomaterials. We offer one of Europe's most advanced mass spectrometry and analysis facility.
Size, size distribution, concentration and zetapotential
Our high-throughput screening facility includes four pipetting robots, allowing efficient and accurate screening of nanomedicine safety and efficacy.
Robotic screening for in vitro efficacy and toxicity in various cells (e.g. cancer cells, normal cells, bacteria)
SINTEF offers a portfolio of preclinical disease models in rodents. The effect, distibution and pharmacokinetics of drugs and nanomedicines is evaluated using multiple imaging- and analytical methods.
The PYROCO2 project will demonstrate the scalability and economic viability of carbon capture and utilization (CCU) to make climate-positive acetone out of industrial CO2 and renewable electricity derived hydrogen.
The gut microbiota are the microorganisms that live in the gastrointestinal tract. They play a fundamental role in health and disease of the host. Detailed understanding of gut microbiota–host interactions is therefore of great importance as this may...
SINTEF want to further develop a targeted treatment strategy that has shown promising effects in animals with patient-derived tumors. The strategy is based on the use of nanoparticles developed by SINTEF containing a cytostatic drug.
An Innovative nanotechnological RNA delivery systems targeting the direct cause of Alzheimer‘s disease instead of its symptoms. The overall objective of B-SMART is to design modular nanoparticles, to manufacture them via a quality-by-design protocol...
